R Squared’s Enliven Therapeutics ELVN Stock Holding History

R Squared’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-650	Closed	-$14.6K	–	651
2024 Q4	$14.6K	Buy	+650	New	+$16.9K	0.01%	1022

Other funds holding ELVN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

R Squared's ELVN Position: Q1 2025 in Review

R Squared sold out of Enliven Therapeutics (ELVN) in Q1 2025, closing a stake of 650 shares — an estimated $14.6K sold.

R Squared first reported a position in ELVN in Q4 2024 and held it in 1 quarter. The position peaked at $14.6K in Q4 2024. 121 funds tracked by Wall St. Rank hold ELVN as of Q1 2025.

R Squared reported no remaining Enliven Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 650 Enliven Therapeutics shares in Q1 2025, an estimated $14.6K.
R Squared first reported a position in Enliven Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Enliven Therapeutics position peaked at $14.6K in Q4 2024.
121 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.